Passa al contenuto
Merck

A0365900

Amikacin sulfate

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

Amikacin disulfate salt

Slide 1 of 1
Autenticati per visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Scegli un formato

Prezzi e disponibilità al momento non sono disponibili

Informazioni su questo articolo

Formula empirica (notazione di Hill):
C22H43N5O13 · 2H2SO4
Numero CAS:
39831-55-5
Peso molecolare:
781.76
Beilstein:
6172633
Numero MDL:
MFCD00167475
Codice UNSPSC:
41116107
ID PubChem:
329770610
NACRES:
NA.24

Documenti fondamentali

Visualizza tutta la documentazione

Vai a

Servizio Tecnico
Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.
Permettici di aiutarti

Grado

pharmaceutical primary standard

Famiglia di API

amikacin

Produttore/marchio commerciale

EDQM

applicazioni

pharmaceutical (small molecule)

Formato

neat

Temperatura di conservazione

2-8°C

Stringa SMILE

OS(O)(=O)=O.OS(O)(=O)=O.NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O

InChI

1S/C22H43N5O13.2H2O4S/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21;2*1-5(2,3)4/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36);2*(H2,1,2,3,4)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+;;/m0../s1
FXKSEJFHKVNEFI-GCZBSULCSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Confronta articoli simili

Visualizza il confronto per intero

Mostra le differenze

1 of 4

Questo articolo
BP8531019494PHR1860
Amikacin sulfate European Pharmacopoeia (EP) Reference Standard

A0365900

Amikacin sulfate

Amikacin sulfate British Pharmacopoeia (BP) Reference Standard

BP853

Amikacin sulfate

Amikacin sulfate United States Pharmacopeia (USP) Reference Standard

USP

1019494

Amikacin sulfate

Amikacin Sulfate Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1860

Amikacin Sulfate

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

certified reference material, pharmaceutical secondary standard

manufacturer/tradename

EDQM

manufacturer/tradename

BP

manufacturer/tradename

USP

manufacturer/tradename

-

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical
pharmaceutical small molecule

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical

format

neat

format

neat

format

neat

format

neat

API family

amikacin

API family

amikacin

API family

amikacin

API family

amikacin

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

−20°C

storage temp.

2-8°C

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Amikacin sulfate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

Prodotto comparabile

N° Catalogo
Descrizione
Determinazione del prezzo

Pittogrammi

Health hazardExclamation mark
GHS08,GHS07

Avvertenze

Warning

Indicazioni di pericolo

H317,H361fd

Classi di pericolo

Repr. 2 - Skin Sens. 1

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

J P Clancy et al.
Thorax, 68(9), 818-825 (2013-06-12)
Arikace is a liposomal amikacin preparation for aerosol delivery with potent Pseudomonas aeruginosa killing and prolonged lung deposition. To examine the safety and efficacy of 28 days of once-daily Arikace in cystic fibrosis (CF) patients chronically infected with P aeruginosa.
Anna Belcarz et al.
International journal of pharmaceutics, 454(1), 285-295 (2013-07-16)
Following the quest for new composite materials for bone tissue engineering, a novel elastic hydroxyapatite-glucan composite loaded with two aminoglycoside antibiotics was prepared. The porosity of the composite and the drug release profiles in closed-loop and semi-open systems were tested.
F D Pien et al.
American journal of hospital pharmacy, 38(7), 981-989 (1981-07-01)
The antibiotic spectrum, pharmacology, adverse effects, and therapeutic use of amikacin sulfate are reviewed. Amikacin, a semisynthetic analog of kanamycin, is highly active against most gram-negative bacteria including many gentamicin-resistant strains. Amikacin's pharmacologic properties have been studied extensively in both
Kenneth S Chen et al.
Pediatric blood & cancer, 60(11), 1772-1777 (2013-06-22)
Children undergoing cancer therapy often receive aminoglycosides to treat febrile neutropenia or gram-negative infections. The magnitude of the risk of developing aminoglycoside-induced ototoxicity and the dose threshold at which that risk significantly increases are unknown. Eligible cancer patients received the
Chien-Wen Huang et al.
International journal of antimicrobial agents, 41(3), 218-223 (2013-01-15)
The occurrence of diseases caused by rapidly growing mycobacteria (RGM) is increasing in Taiwan. In this study, the in vitro antimicrobial activities of tigecycline, minocycline, tetracycline and doxycycline were evaluated against 160 clinical RGM isolates, including 34 Mycobacterium abscessus sensu
Visualizza tutti i documenti correlati

Domande

Recensioni

Nessuna valutazione

Filtri attivi

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica